Pacific Biosciences
PACB
99 hedge funds and large institutions have $331M invested in Pacific Biosciences in 2018 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 38 increasing their positions, 26 reducing their positions, and 10 closing their positions.
72% more capital invested
Capital invested by funds: $193M → $331M (+$138M)
46% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 26
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.2% less ownership
Funds ownership: 71.88% → 70.68% (-1.2%)
2% less funds holding
Funds holding: 101 → 99 (-2)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
63% less call options, than puts
Call options by funds: $182K | Put options by funds: $495K
Top Buyers
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$5.65M |
| 2 |
BC
Broadfin Capital
New York
|
+$2.92M |
| 3 |
BlackRock
New York
|
+$2.36M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.22M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.01M |
Top Sellers
| 1 |
RCM
Raging Capital Management
Rocky Hill,
New Jersey
|
-$6.8M |
| 2 |
Blackstone Inc
New York
|
-$4.75M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$2.55M |
| 4 |
TA
Teachers Advisors
New York
|
-$2.26M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$901K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Walleye Trading
New York
| – | -$135K | -66,000 | Closed |
|
102
SG Americas Securities
New York
| – | -$58K | -28,103 | Closed |
|
|
VF
103
Virtu Financial
New York
| – | -$50K | -24,424 | Closed |
|
|
TRCT
104
Tower Research Capital (TRC)
New York
| – | -$43K | -20,841 | Closed |
|
105
Balyasny Asset Management
Chicago,
Illinois
| – | -$41K | -19,958 | Closed |
|
106
Parallax Volatility Advisers
San Francisco,
California
| – | -$24K | -11,896 | Closed |
|
|
PHK
107
Point72 Hong Kong
Hong Kong
| – | -$2K | -1,127 | Closed |
|
PACB Hedge Fund Activity: Q2 2018 in Review
99 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q2 2018, worth a combined $331M — up 72% from $193M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of PACB and 8 opened new positions — a net loss of 2 holders — while 26 trimmed existing stakes and 38 added.
The largest buyer was ARK Investment Management, adding an estimated $5.65M. The largest seller was Raging Capital Management, exiting entirely with an estimated $6.8M sold.
- 99 institutional investors held Pacific Biosciences (PACB) as of Q2 2018, down from 101 in Q1 2018.
- Funds reported $331M of Pacific Biosciences stock for Q2 2018, up 72% quarter-over-quarter.
- 8 funds opened new Pacific Biosciences positions in Q2 2018 and 10 closed out, a net change of -2 holders.
- The largest Pacific Biosciences buyer in Q2 2018 was ARK Investment Management, an estimated $5.65M added.
- The largest Pacific Biosciences seller in Q2 2018 was Raging Capital Management, an estimated $6.8M sold.
Based on aggregated 13F filings for Q2 2018.